[Clinicopathological features of intravascular peripheral T-cell lymphoma] [0.03%]
血管内皮淋巴细胞型T细胞淋巴瘤的临床病理特征
X Guan,Y C Yang,Y Qi et al.
X Guan et al.
Objective: To summarize the clinical and pathological features of intravascular NK and T cell lymphoma for better understanding of such disease to reduce misdiagnosis and miss-diagnosis. Methods: Clinical and pathological features were anal...
[Chronic lymphocytic leukemia with t (14;18) (q32;q21) : report of eight cases and a literature review] [0.03%]
慢性淋巴细胞白血病t(14;18)(q32;q21)染色体异常八例临床分析及文献复习
J Li,H R Zhang,H Qiu et al.
J Li et al.
Objective: The study aimed to analyze the clinical features and prognosis of chronic lymphocytic leukemia (CLL) with t (14;18) (q32;q21) and conduct a literature review. Methods: The clinical data of 8 patients with CLL carrying t (14;18) (...
[Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions] [0.03%]
大肿块复发/难治B细胞淋巴瘤患者回输CD19-CART的局部反应及疗效分析
Q Li,H B Deng,M J Liu et al.
Q Li et al.
Objective: To observe the local reactions and efficacy of CD19 CAR-T therapy in recurrence/refractory B-cell non-Hodgkin's lymphoma (R/R NHL) patients with >7.5 cm lesions. Methods: 32 R/R NHL patients with >7.5 cm lesions were enrolled and...
[Clinical characteristics and prognostic risk factors analysis of carbapenem-resistant organism in the department of hematology] [0.03%]
[耐碳青霉烯类药物病原体的临床特征和预后危险因素分析(血液科)]
S Z Chen,J J Xu,T T Xiao et al.
S Z Chen et al.
Objective: To study the distribution and drug resistance of Carbapenem-Resistant Organism (CRO) and to analysis the risk factors of CRO 30-day mortality. Methods: A total of 181 patients with CRO infection diagnosed in Department of Hematol...
[Analysis of gene mutation spectrum and pharmacokinetics of fibrinogen infusion in 146 cases of congenital fibrinogen disorders] [0.03%]
先天性纤维蛋白原缺陷病基因突变谱及纤维蛋白原输注药代动力学分析
L Y Huang,D L Zhang,R F Fu et al.
L Y Huang et al.
Objective: To investigate the clinical type and gene mutations, clinical manifestations, laboratory tests, diagnosis, and fibrinogen replacement therapy of congenital fibrinogen disorders. Methods: Clinical data of 146 patients with congeni...
[Unrelated cord blood stem cell transplantation for high-risk/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases] [0.03%]
高危/难治性儿童急性髓系白血病无关脐带血移植临床分析(160例)
E L Chen,H L Liu,L Q Geng et al.
E L Chen et al.
Objective: To retrospectively analyze the clinical outcomes of single unrelated cord blood transplantation (UCBT) in children with high risk and refractory acute myeloid leukemia (AML) . Methods: Between June 2008 and December 2018, a total...
[Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia] [0.03%]
氟达拉滨联合环磷酰胺和利妥昔单抗治疗43例慢性淋巴细胞白血病临床分析
T Y Wang,S H Yi,Y Wang et al.
T Y Wang et al.
Objective: To investigate the efficacy of fludarabine and cyclophosphamide combined with rituximab (FCR) in previously untreated patients with chronic lymphocytic leukemia (CLL) . Methods: The clinical data of 43 enrolled patients from May ...
[Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020] [0.03%]
2020年我国慢性髓性白血病患者酪氨酸激酶抑制剂使用现状调查
H F Wang,Y L Zhang,X L Liu et al.
H F Wang et al.
Objective: To investigate the current status of treatment choice and responses in patients with chronic myeloid leukemia (CML) in China. Methods: From the end of April to mid-May in 2020, a cross-sectional survey, by filling out a survey qu...
[The consensus of the diagnosis and treatment of Castleman disease in China (2021)] [0.03%]
中国Castleman病诊断和治疗的专家共识(2021)
Hematology Committee of Chinese Medical Association;Hematological Oncology Committee of China Anti-Cancer Association;China Castleman Disease Network (CCDN)
Hematology Committee of Chinese Medical Association;Hematological Oncology Committee of China Anti-Cancer Association;China Castleman Disease Network (CCDN)